Development of predictive marker of drug therapy for colorectal cancer by epigenetic analysis of circulating DNA
| Project/Area Number |
21590802
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHASHI Masanobu 東北大学, 病院, 助教 (00447161)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 下部消化管学 / エピジェネティクス / メチル化 / 大腸癌 |
|---|
| Research Abstract |
Forty three chemotherapy-refractory Japanese patients with mCRC were treated with cetuximab monotherapy or cetuximab plus irinotecan. KRAS, BRAF and PIK3CA mutational status of tumors were assessed. The wild-type subgroup without any mutations in the KRAS, BRAF and PIK3CA had a better RR (37. 0%)and PFS (6. 4 months)than did the wild-type KRAS subgroup. Our data indicated that KRAS status is predictive of cetuximab response in the Japanese population. The additional analysis of BRAF and PIK3CA genes in wild-type KRAS patients could improve the selection of the patients who are most likely to benefit from anti-EGFR antibody therapy.
|
Report
(4 results)
Research Products
(31 results)
-
[Journal Article] Clinical usefulness of KRAS, BRAF and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan-and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer2012
Author(s)
Soeda, H., Shimodaira, H., Watanabe, M., Suzuki, T., Gamoh, M., Mori, T., Komine, K., Iwama, N., Kato, S., Ishioka, C.
-
Journal Title
Int J Clin Oncol
Volume: (in press)
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
[Journal Article]2009
Author(s)
下平秀樹、石岡千加史
-
Journal Title
がん化学療法・分子標的治療 update(中外医学者)
Pages: 184-188
Related Report
-
[Presentation] Phase II intermittent (or stop and go) 1-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC : The interim report of T-CORE09012012
Author(s)
Gamoh, E., Kato, S., Niitani, T., Murakawa, Y., Sakayori, M., Isobe, H., Shimodaira, H., Akiyama, S., Yoshida, K., Yoshioka, T.
Organizer
American Society of Clinical Oncology, Gastrointestinal Cancers Symposium 2011
Place of Presentation
San Francisco,アメリカ
Year and Date
2012-01-20
Related Report
-
-
-
-
[Presentation] 石岡千加史:大腸癌における抗EGFR抗体薬のバイオマーカーEGFRシグナル伝達因子検索の意義2010
Author(s)
添田大司, 下平秀樹, 小峰啓吾, 加藤俊介, 森隆弘, 角道祐一, 大堀久詔, 高橋信, 秋山聖子, 鈴木貴夫, 蒲生真紀夫, 渡辺みか, 岩間憲行, 鈴木博義
Organizer
第48回日本癌治療学会学術集会
Place of Presentation
京都
Year and Date
2010-10-29
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
